Abstract 1879P
Background
Cancer affects many aspects of life and can have negative consequences such as reducedː health and quality of life and mental disorders. Cancer patients face most of the stressors associated with diagnosis and treatment. The aim of this study is investigating the effect of family support on the mental health of patients with breast Cancer.
Methods
This cross-sectional study examined 70 breast cancer patients who were referred within 6 months to Imam Khomeini and Shohadah Ha* Tir Hospitals for radiotherapy, chemotherapy or follow- up treatment. In terms of mental health, these patients were assessed using the criteria of hospital anxiety and depression and distress thermometer, and the level of family support using the McMaster Family Assessment Device and attachment style criteria. The psychiatric interview with the patients was conducted by the psychiatric resident and all questionnaires were completed by her in face-to-face interviews or video calls with the patient. Before the start of the study, all patients gave written informed consent. The Family Support Questionnaire contains 60 questions that identify the structural, professional, and interactive characteristics of the family. This questionnaire has 7 subscales.
Results
The mean (standard deviation) of the total score on the Family Support Questionnaire for the subjects studied was 15.7 (2.96) with a range of 9.87 to 21.06. the mean (standard deviation) of anxiety and depression scores were 9.68 (5.34) and 8.34 (4.41), respectively. the results show that increasing the score on anxiety and depression significantly increases family support and its sub-comparisons.
Conclusions
The study revealed that the mean scores of the depression and anxiety in breast cancer patients is more than normal limitation. The results showed that decreasing family support and its sub- comparisons (an increase in the score indicates an unhealthy situation) significantly increases anxiety and depression in these individuals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Iran University of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1877P - Meaning-making in the re-entry phase: A qualitative focus group study with patients with breast cancer and melanoma
Presenter: Anna Visser
Session: Poster session 05
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05